<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">zdor</journal-id><journal-title-group><journal-title xml:lang="ru">Проблемы здоровья и экологии</journal-title><trans-title-group xml:lang="en"><trans-title>Health and Ecology Issues</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2220-0967</issn><issn pub-type="epub">2708-6011</issn><publisher><publisher-name>Gomel State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.51523/2708-6011.2023-20-4-19</article-id><article-id custom-type="elpub" pub-id-type="custom">zdor-2659</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>НОВЫЕ ТЕХНОЛОГИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>NEW TECHNOLOGIES</subject></subj-group></article-categories><title-group><article-title>Определение первичной резистентности Helicobacter pylori к левофлоксацину в образцах биоптатов слизистой оболочки желудка с использованием полимеразной цепной реакции в реальном времени</article-title><trans-title-group xml:lang="en"><trans-title>Determination of Helicobacter pylori primary resistance to levofloxacin in gastric mucosal biopsy samples using real-time polymerase chain reaction</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0213-2421</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Воропаева</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Voropaeva</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Воропаева Алла Викторовна, к.б.н., доцент, врач клинической лабораторной диагностики</p><p> Гомель</p></bio><bio xml:lang="en"><p>Alla V. Voropaeva, Candidate of Biological Sciences, As- sociate Professor, Doctor of Clinical Laboratory Diagnostics</p><p> Gomel</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0579-6215</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шевченко</surname><given-names>Н. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Shevchenko</surname><given-names>N. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шевченко Наталья Ивановна, к.м.н., доцент, заведующий лабораторией клеточных технологий</p><p> Гомель</p></bio><bio xml:lang="en"><p>Natalia I. Shevchenko, Candidate of Medical Sciences, Associate Professor, Head of the Department of Laboratory</p><p>Gomel</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Республиканский научно-практический центр радиационной медицины и экологии человека</institution></aff><aff xml:lang="en"><institution>Republican Research Center for Radiation Medicine and Human Ecology</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>05</day><month>01</month><year>2024</year></pub-date><volume>20</volume><issue>4</issue><elocation-id>149–154</elocation-id><permissions><copyright-statement>Copyright &amp;#x00A9; Воропаева А.В., Шевченко Н.И., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Воропаева А.В., Шевченко Н.И.</copyright-holder><copyright-holder xml:lang="en">Voropaeva A.V., Shevchenko N.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.gsmu.by/jour/article/view/2659">https://journal.gsmu.by/jour/article/view/2659</self-uri><abstract><p>Цель исследования. Изучить первичную резистентность Helicobacter pylori (H. pylori) к левофлоксацину у жителей Гомельской области методом полимеразной цепной реакции в реальном времени (ПЦР РВ).Материалы и методы. В исследование включено 170 пациентов с диагнозом «Гастрит и дуоденит», K29, медиана возраста — 48,5 года (25 и 75 % — 37 и 61 год). Согласно анкетным данным пациентов, эрадикационная терапия с применением левофлоксацина им не проводилась. Для определения резистентности H. pylori к левофлоксацину использовали метод ПЦР РВ.Результаты. Из 170 исследуемых образцов ДНК 8 образцов имели сомнительный результат и согласно методике учета результатов подлежат перестановке с этапа выделения ДНК. Остальные 162 образца являлись положительными по гену β-актин (внутренний контрольный образец — ВКО) и учитывались при дальнейшем анализе (Ct, CY5 19,6–27,4). ДНК гена 16sRNA (Ct, ROX 19,5–30,04), cвидетельствующая об инфицировании бактерией, подтверждена в 152 образцах (93,8 %). ДНК гена gyrA (точечные мутации А259T, Т261C, G261A, G271A, G271T и A272G) выявлена в 19 из 152 образцов ДНК, и резистентность H. pylori к левофлоксацину составила 12,5 %, (Ct, Hex 23,2–30,7). Заведомо положительные контрольные пробы имели характерный рост кривых по соответствующим каналам детекции, в заведомо отрицательных — рост кривых не отмечен.Заключение. Первичная резистентность H. pylori к левофлоксацину у жителей Гомельской области составила 12,5 %. Мутации гена gyrA являются наиболее чувствительным маркером для прогнозирования успешной эрадикации при использовании фторхинолонов, в частности левофлоксацина. ПЦР РВ является надежным методом выявления мутаций и позволяет проводить одновременное выявление ДНК H. pylori и резистентности к левофлоксацину, что значительно сокращает время исследования. </p></abstract><trans-abstract xml:lang="en"><p>Objective. To study the primary resistance of Helicobacter pylori (H. pylori) to levofloxacin in residents of Gomel region by real-time polymerase chain reaction (RT PCR).Materials and methods. The study included 170 patients diagnosed with gastritis and duodenitis, K29, median age - years (25% and 75% 37 and 61 years). According to the questionnaire data of the patients, eradication therapy with levofloxacin was not performed for them. To determine the resistance of H. pylori to levofloxacin we used RT PCR. Results. Out of 170 DNA samples analyzed, 8 samples had doubtful results and according to the methodology for recording the results are subject to rearrangement from the DNA isolation stage. The remaining 162 samples were positive for the β-actin gene (internal control sample ICS) and were taken into account in further analysis (Ct, CY5 19.6-27.4). 16sRNA gene DNA (Ct, ROX 19.5-30.04), indicative of bacterial infection, was confirmed in 152 samples (93.8%). DNA of the gyrA gene (point mutations A259T, T261C, G261A, G271A, G271T and A272G) was detected in 19 of 152 DNA samples, and H. pylori resistance to levofloxacin was 12.5 %, (Ct, Hex 23.2-30.7). The positive control samples had characteristic curve growth on the corresponding detection channels, while the negative samples showed no curve growth.Conclusion. Primary resistance of H. pylori to levofloxacin in residents of Gomel region amounted to 12.5%. Mutations of gyrA gene are the most sensitive marker for predicting successful eradication when using fluoroquinolones, in particular levofloxacin. RT PCR is a reliable method of mutation detection and allows simultaneous detection of H. pylori DNA and resistance to levofloxacin, which significantly reduces the study time.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>H. pylori</kwd><kwd>праймеры</kwd><kwd>полимеразная цепная реакция в реальном времени</kwd><kwd>левофлоксацин</kwd><kwd>резистентность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>H. pylori</kwd><kwd>primers</kwd><kwd>real-time polymerase chain reaction</kwd><kwd>levofloxacin</kwd><kwd>primary resistance</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Диагностика и лечение пациентов с заболеваниями органов пищеварения [Электронный ресурс]: клинический протокол: постановление Министерства здравоохранения Респ. Беларусь, 01 июня 2017 г., № 54, прил. 2. [дата обращения 2023 ноябрь 01]. Режим доступа: https://pravo.by/document/?guid=12551&amp;p0=W21732115p&amp;p1=1</mixed-citation><mixed-citation xml:lang="en">Diagnosis and treatment of patients with diseases of the digestive system: clinical protocol [Electronic resource]: resolution of the Ministry of Health of the Republic of Belarus, June 01, 2017, No. 54, App. 2. [date of access 2023 Nov 01]. Available from: https://pravo.by/document/?guid=12551&amp;p0=W21732115p&amp;p1=1</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022 Aug 8: gutjnl-2022-327745. DOI: https://doi.org/10.1136/gutjnl-2022-327745</mixed-citation><mixed-citation xml:lang="en">Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022 Aug 8: gutjnl-2022-327745. DOI: https://doi.org/10.1136/gutjnl-2022-327745</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Yeo YH, Hsu CC, Lee CC, Ho HJ, Lin JT, Wu MS, et al. Taiwan Gastrointestinal Disease and Helicobacter Consortium. Systematic review and network meta-analysis: Comparative effectiveness of therapies for second-line Helicobacter pylori eradication. J Gastroenterol Hepatol. 2019 Jan;34(1):59-67. DOI: https://doi.org/10.1111/jgh.14462</mixed-citation><mixed-citation xml:lang="en">Yeo YH, Hsu CC, Lee CC, Ho HJ, Lin JT, Wu MS, et al. Taiwan Gastrointestinal Disease and Helicobacter Consortium. Systematic review and network meta-analysis: Comparative effectiveness of therapies for second-line Helicobacter pylori eradication. J Gastroenterol Hepatol. 2019 Jan;34(1):59-67. DOI: https://doi.org/10.1111/jgh.14462</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther. 2007 Aug 1;26(3):343-357. DOI: https://doi.org/10.1111/j.1365-2036.2007.03386.x</mixed-citation><mixed-citation xml:lang="en">Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther. 2007 Aug 1;26(3):343-357. DOI: https://doi.org/10.1111/j.1365-2036.2007.03386.x</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Chen J, Li P, Huang Y, Guo Y, Ding Z, Lu H. Primary Antibiotic Resistance of Helicobacter pylori in Different Regions of China: A Systematic Review and Meta-Analysis. Pathogens. 2022 Jul 12;11(7):786. DOI: https://doi.org/10.3390/pathogens11070786</mixed-citation><mixed-citation xml:lang="en">Chen J, Li P, Huang Y, Guo Y, Ding Z, Lu H. Primary Antibiotic Resistance of Helicobacter pylori in Different Regions of China: A Systematic Review and Meta-Analysis. Pathogens. 2022 Jul 12;11(7):786. DOI: https://doi.org/10.3390/pathogens11070786</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ho JJC, Navarro M, Sawyer K, Elfanagely Y, Moss SF. Helicobacter pylori Antibiotic Resistance in the United States Between 2011 and 2021: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2022 Aug 1;117(8):1221-1230. DOI: https://doi.org/10.14309/ajg.0000000000001828</mixed-citation><mixed-citation xml:lang="en">Ho JJC, Navarro M, Sawyer K, Elfanagely Y, Moss SF. Helicobacter pylori Antibiotic Resistance in the United States Between 2011 and 2021: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2022 Aug 1;117(8):1221-1230. DOI: https://doi.org/10.14309/ajg.0000000000001828</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Андреев Д.Н., Маев И.В., Кучерявый Ю.А. Резистентность Helicobacter pylori в Российской Федерации: метаанализ исследований за последние 10 лет. Терапевтический архив. 2020;92(11):2-30. DOI: https://doi.org/10.26442/00403660.2020.11.000795</mixed-citation><mixed-citation xml:lang="en">Andreev DN, Maev IV, Kucheryavyy YA. Helicobacter pylori resistance in the Russian Federation: a meta-analysis of studies over the past 10 years. Therapeutic Archive. 2020;92(11):24-30. DOI: https://doi.org/10.26442/00403660.2020.11.000795</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Fallone CA, Moss SF, Malfertheiner P. Reconciliation of Recent Helicobacter pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics. Gastroenterology. 2019 Jul;157(1):44-53. DOI: https://doi.org/10.1053/j.gastro.2019.04.011</mixed-citation><mixed-citation xml:lang="en">Fallone CA, Moss SF, Malfertheiner P. Reconciliation of Recent Helicobacter pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics. Gastroenterology. 2019 Jul;157(1):44-53. DOI: https://doi.org/10.1053/j.gastro.2019.04.011</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kim SY, Chung J-W. Best Helicobacter pylori Eradication Strategy in the Era of Antibiotic Resistance. Antibiotics. 2020;9(8):436. DOI: https://doi.org/10.3390/antibiotics9080436</mixed-citation><mixed-citation xml:lang="en">Kim SY, Chung J-W. Best Helicobacter pylori Eradication Strategy in the Era of Antibiotic Resistance. Antibiotics. 2020;9(8):436. DOI: https://doi.org/10.3390/antibiotics9080436</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">López-Gasca M, Peña J, García-Amado MA, Michelangeli F, Contreras M. Point Mutations at gyrA and gyrB Genes of Levofloxacin-Resistant Helicobacter pylori Isolates in the Esophageal Mucosa from a Venezuelan Population. Am J Trop Med Hyg. 2018 Apr;98(4):1051-1055. DOI: https://doi.org/10.4269/ajtmh.17-0478</mixed-citation><mixed-citation xml:lang="en">López-Gasca M, Peña J, García-Amado MA, Michelangeli F, Contreras M. Point Mutations at gyrA and gyrB Genes of Levofloxacin-Resistant Helicobacter pylori Isolates in the Esophageal Mucosa from a Venezuelan Population. Am J Trop Med Hyg. 2018 Apr;98(4):1051-1055. DOI: https://doi.org/10.4269/ajtmh.17-0478</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Nishizawa T, Suzuki H. Mechanisms of Helicobacter pylori antibiotic resistance and molecular testing. Front Mol Biosci. 2014 Oct 24;1:19. DOI: https://doi.org/10.3389/fmolb.2014.00019</mixed-citation><mixed-citation xml:lang="en">Nishizawa T, Suzuki H. Mechanisms of Helicobacter pylori antibiotic resistance and molecular testing. Front Mol Biosci. 2014 Oct 24;1:19. DOI: https://doi.org/10.3389/fmolb.2014.00019</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Guevara B, Cogdill AG. Helicobacter pylori: A Review of Current Diagnostic and Management Strategies. Dig Dis Sci. 2020 Jul;65(7):1917-1931. DOI: https://doi.org/10.1007/s10620020-06193-7</mixed-citation><mixed-citation xml:lang="en">Guevara B, Cogdill AG. Helicobacter pylori: A Review of Current Diagnostic and Management Strategies. Dig Dis Sci. 2020 Jul;65(7):1917-1931. DOI: https://doi.org/10.1007/s10620020-06193-7</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Организация работы при исследованиях методом ПЦР материала инфицированного патогенными биологическими агентами III-IY групп патогенности [Электронный ресурс]: методические указания МУ 1.3.179403, МУ 1.3.1794-04. Минздрав России. 2003. – Прил. 7. [дата обращения 2023 ноябрь 01]. Режим доступа: https://meganorm.ru/Data2/1/4293855/4293855457.htm</mixed-citation><mixed-citation xml:lang="en">Organization of work during PCR research of material contaminated with pathogenic biological agents of III-IY pathogenicity groups [Electronic resource]: methodological recommendations MU 1.3.1794-03, MU 1.3.1794-04. Ministry of Health of Russia. 2003. – App. 7. [date of access 2021 Nov 01]. Available from: https://meganorm.ru/Data2/1/4293855/4293855457.htm</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Li Y, Lv T, He C, Wang H, C David S, et al. Evaluation of multiplex ARMS-PCR for detection of Helicobacter pylori mutations conferring resistance to clarithromycin and levofloxacin. Gut Pathog. 2020;12: Article 35. DOI: https://doi.org/10.1186/s13099-020-00373-6</mixed-citation><mixed-citation xml:lang="en">Li Y, Lv T, He C, Wang H, C David S, et al. Evaluation of multiplex ARMS-PCR for detection of Helicobacter pylori mutations conferring resistance to clarithromycin and levofloxacin. Gut Pathog. 2020;12: Article 35. DOI: https://doi.org/10.1186/s13099-020-00373-6</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology. 2018 Nov;155(5):13721382.e17. DOI: https://doi.org/10.1053/j.gastro.2018.07.007</mixed-citation><mixed-citation xml:lang="en">Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology. 2018 Nov;155(5):13721382.e17. DOI: https://doi.org/10.1053/j.gastro.2018.07.007</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibioticresistant bacteria and tuberculosis. Lancet Infect Dis. 2018 Mar;18(3):318-327. DOI: https://doi.org/10.1016/S1473-3099(17)30753-3</mixed-citation><mixed-citation xml:lang="en">Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibioticresistant bacteria and tuberculosis. Lancet Infect Dis. 2018 Mar;18(3):318-327. DOI: https://doi.org/10.1016/S1473-3099(17)30753-3</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Shah SC, Iyer PG, Moss SF. AGAClinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review. Gastroenterology. 2021 Apr;160(5):1831-1841. DOI: https://doi.org/10.1053/j.gastro.2020.11.059</mixed-citation><mixed-citation xml:lang="en">Shah SC, Iyer PG, Moss SF. AGAClinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review. Gastroenterology. 2021 Apr;160(5):1831-1841. DOI: https://doi.org/10.1053/j.gastro.2020.11.059</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Sah S, Chen L, Houghton J, Kemppainen J, Marko AC, Zeigler R, Latham GJ. Functional DNA quantification guides accurate next-generation sequencing mutation detection in formalin-fixed, paraffin-embedded tumor biopsies. Genome Med. 2013 Aug 30;5(8):77. DOI: https://doi.org/10.1186/gm481</mixed-citation><mixed-citation xml:lang="en">Sah S, Chen L, Houghton J, Kemppainen J, Marko AC, Zeigler R, Latham GJ. Functional DNA quantification guides accurate next-generation sequencing mutation detection in formalin-fixed, paraffin-embedded tumor biopsies. Genome Med. 2013 Aug 30;5(8):77. DOI: https://doi.org/10.1186/gm481</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
